In February 2014, the EMCDDA and Europol examined the available information on a new psychoactive substance, 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (commonly known by the abbreviation 4,4'-DMAR). The two organisations concluded that sufficient information had been accumulated to merit the production of a Joint Report on 4,4'-DMAR as stipulated by Article 5.1 of the Council Decision.